Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05534776
Other study ID # IGA Pemphigus
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 21, 2022
Est. completion date August 30, 2023

Study information

Verified date September 2022
Source Premier Specialists, Australia
Contact Bianca Wills
Phone 0452409850
Email premierspectrialsbianca@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to explore the reliability and validity of newly developed Investigator Global Assessments (IGAs) in scoring the severity of pemphigus. IGAs are simple 5-point scales ranging from clear - severe and are preferred by the FDA as endpoints in clinical trials.


Description:

This study aims to obtain statistical data regarding the inter-rater and intra-rater reliability of the IGAs, Pemphigus Disease Activity Index (PDAI) and Autoimmune Bullous Skin Disease Intensity Score (ABSIS) as well as the convergent validity of the IGAs with the PDAI and objective component of the ABSIS. Photograph sets of pemphigus lesions will be gathered from the lead site and participant sites. They will be de-identified and printed in a two hardcopy booklets; the first containing 20 photo sets and the second containing 17 new photo sets and 3 repeat photo sets. In the first part of the study, 8 dermatologists will score 20 sets of photographs of pemphigus lesions (a mixture of skin and mucosal lesions), using the IGAs for pemphigus as well as the PDAI and ABSIS. The first booklet will be mailed to dermatologists and they will use the booklet to score each photo set and will submit their scores in a confidential online survey. In the second part of the study, the second booklet will be sent to dermatologists in the same manner 4 weeks later, and each dermatologist will score the photo sets using the same scoring tools. It is estimated that each scoring session will take two hours to complete. Data gathered here will allow for calculation of inter-rater reliability and intra-rater reliability of the IGAs and convergent validity of the IGAs with PDAI and ABSIS. Later, a sub-study will occur to calculate minimal clinically important differences (MCID) for the IGAs and PDAI. This will involve scoring pemphigus severity of patients at Premier Specialists using PDAI and IGA scores and a Likert score to classify patients as improved, stable or deteriorated compared to previous visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date August 30, 2023
Est. primary completion date August 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Having pemphigus diagnosed by a qualified dermatologist - Aged 18 or older at the time of photography Exclusion Criteria: - Those whose photographs are unable to be adequately de-identified

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Investigator Global Assessments (IGAs)
5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.

Locations

Country Name City State
Australia Premier Specialists Kogarah New South Wales
Bulgaria Medical University of Sofia Sofia
Greece Aristotle University of Thessaloniki Thessaloníki
Iran, Islamic Republic of Razi Hospital Tehran
Israel Tel Aviv Medical Centre Tel Aviv
Singapore National University Hospital of Singapore Singapore
Turkey Akdeniz University Hospital Antalya

Sponsors (1)

Lead Sponsor Collaborator
Premier Specialists, Australia

Countries where clinical trial is conducted

Australia,  Bulgaria,  Greece,  Iran, Islamic Republic of,  Israel,  Singapore,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary IGA-PV-M (D/P/F), IGA-PV-S (D/P/F), IGA-PF (D/P/F) IGA score of pemphigus severity, possible score from 0-4 Baseline
Primary Pemphigus Disease Activity Index (PDAI) Score Possible score from 0-263 Baseline
Primary Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) Possible score from 0-206 Baseline
See also
  Status Clinical Trial Phase
Terminated NCT00278642 - Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders Phase 1
Not yet recruiting NCT05898308 - Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus Phase 4
Terminated NCT01559155 - Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
Active, not recruiting NCT01974518 - Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus Phase 3
Recruiting NCT05284929 - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Recruiting NCT05954416 - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Completed NCT00283712 - Use of Infliximab for the Treatment of Pemphigus Vulgaris Phase 2
Not yet recruiting NCT06285435 - Coagulation Activation in Patients With Pemphigus
Not yet recruiting NCT06454357 - A Clinical Study of B007 in the Treatment of Pemphigus. Phase 2/Phase 3
Completed NCT01299857 - Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab Phase 3
Completed NCT00960713 - The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders N/A
Completed NCT00213512 - Effect of Anti CD20 in Pemphigus Desease Phase 2/Phase 3
Active, not recruiting NCT04400994 - IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus Phase 2
Recruiting NCT02237313 - Identification of Vulnerability Factors in the Course of Pemphigus Patients N/A
Terminated NCT03075904 - A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Phase 1/Phase 2
Terminated NCT03762265 - A Study of PRN1008 in Patients With Pemphigus Phase 3
Recruiting NCT02365675 - Wound Dressings for Pemphigus and Pemphigoid N/A
Recruiting NCT01338103 - Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex N/A
Active, not recruiting NCT00656656 - Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus Phase 2
Completed NCT00127764 - European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus Phase 2/Phase 3